Spots Global Cancer Trial Database for Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids
Official Title: A Phase III Multicenter Extension Study Evaluating the Safety of 25 and 50 mg Proellex® in the Treatment of Women Who Have Completed ZPU-301, ZPU-302, ZPU-303, or ZPU-304
Study ID: NCT01069120
Conditions
Study Description
Brief Summary: Safety and efficacy study of 25 and 50 mg doses of Proellex
Detailed Description: The study is intended to provide more abundant safety and efficacy data of both the 25 and 50 mg doses of Proellex than ZPU-301, ZPU-302, ZPU-303 and ZPU-304 alone.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: Yes
Locations
Visions Clinical Research, Boynton Beach, Florida, United States
Insignia Clinical Research (Tampa Bay Women's Center), Tampa, Florida, United States
Advances in Health Inc, Houston, Texas, United States
The Women's Hospital of Texas, Clinical Research Center, Houston, Texas, United States
Contact Details
Name: Andre vanAS, PhD, Md
Affiliation: Repros Therapeutics Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
